FDA Inspection
Chartwell Pharmaceuticals LLCChartwell Pharmaceuticals LLC – FDA Inspection, May 31, 2024
Record Details
This FDA Inspection record concerns Chartwell Pharmaceuticals LLC, with an inspection on May 31, 2024, issued by the New York District Office, covering human drugs.
View Company Profile
ID · 3dfcf0f2-695e-4a28-bd9d-da2684dfb317
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1236033
- FDA center
- Human Drugs
- Project area
- Generic Drug Evaluation
FDA Citations
5- 21 CFR 211.100(a)Changes to Procedures Not Reviewed, Approved
- 21 CFR 211.100(b)Procedure Deviations Recorded and Justified
- 21 CFR 211.160(b)(3)Drug products-sampling procedures/specifications
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.63Equipment Design, Size and Location
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Chartwell Pharmaceuticals LLC
8| Date | Classification | Office | Project area |
|---|---|---|---|
| November 18, 2025 | OAI | New York District Office | Drug Quality Assurance |
| December 19, 2024 | Not classified | New York District Office | Drug Quality Assurance |
| April 8, 2024 | VAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| May 24, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 26, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Chartwell Pharmaceuticals LLC
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.